Address correspondence to Dr Amy A. Gelfand, University of California, San Francisco, Department of Pediatrics, 550 16th St, 4th floor, Box 0137, San Francisco, CA 94158, email@example.com.
RELATIONSHIP DISCLOSURE: Dr Gelfand has received personal compensation for serving on the medical advisory board of eNeura Inc; as associate editor for JAMA Neurology; and as a consultant for Biohaven Pharmaceutical, Eli Lilly and Company, and Zosano Pharma Corporation. Continued on page 1136Dr Gelfand has received research/grant support from eNeura Inc, the Migraine Research Foundation, the National Institutes of Health/National Center for Advancing Translational Sciences, and the University of California San Francisco Weill Institute for the Neurosciences. Dr Gelfand has received publishing royalties from UpToDate, Inc and has received compensation as a legal consultant.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Gelfand discusses the unlabeled/investigational use of all listed medications for the treatment of headache in children and adolescents, with the exceptions of almotriptan oral tablets, sumatriptan/naproxen combination tablets, and zolmitriptan nasal spray for adolescents 12 to 17 years of age for the treatment of acute migraine as well as topiramate in adolescents 12 to 17 years of age for migraine prevention. Rizatriptan is labeled for acute migraine treatment in children age 6 and older.
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE
SUPPLEMENTAL DIGITAL CONTENT (SDC) AVAILABLE ONLINE